The effect of hesperidin administration on endothelial function and gut barrier functio

Completed

• Conditions: verstoringen in intestinale barrierfunctie; metabolic syndrome; obesity; overweight; 10047066

• Registration Number: NL-OMON38722
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-10-17
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 68

Inclusion Criteria

Men/women, BMI 25-35 kg/m2, healthy human beings, age 18-70 years, fasting glucose <7.0 mmol/L, Hba1c between 4.4-6.2%

Exclusion Criteria

Type 2 diabetes mellitus; gastroenterological diseases or abdominal surgery; cardiovascular diseases; cancer; liver or kidney malfunction; disease with life expectancy shorter than 5 years; self admitted HIV-positive status; abuse of products such as alcohol (> 20 alcoholic consumptions per week) or drugs; smoking; plans to lose weight or following a hypocaloric diet; weight gain or loss > 3 kg in previous 3 months; use of medication interfering with endpoints (intake of antihypertensive medication, statins, corticosteroids, NSAIDs, ciclosporin A, rifampicin is strictly forbidden); use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets, or in alternative medicine; hormone replacement therapy, use of antibiotics in the 90 days prior to the start of study; known pregnancy, lactatation; history of side effects towards intake of flavonoids or citrus fruits; administration of investigational drugs or participating in any scientific intervention study which may interfere with this study ( to be decided by principal investigator) in the 180 days prior to the study; blood donation within 3 months before study period; Failure to comply prohibited intake of hesperidin containing food products during study period and prohibited intake of food products that are able to influence FMD measurements one day prior to test days.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of this study is to evaluate the efficacy of Cordiart* on<br /><br>endothelial function, as assessed by flow mediated dilatation (FMD)<br /><br>measurements, after 6 weeks of administration.</p><br>